Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
Onconova To Continue Additional Cohorts In Rigosertib Lung Cancer Trial
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Rigosertib Combination Phase 1/2a Trial To Continue Onconova announced the completion of three cohorts in its Phase 1/2a trial testing rigosertib in combination with the checkpoint inhibitor nivolumab (Opdivo). The data show signs of efficacy without reaching a maximum tolerated dose, justifying continuing the trial with higher dosing. We see this continuation and higher dosing as a positive signal of efficacy and safety.
Interim Data Should Indicate Improved Responses The announcement indicates evidence of efficacy without side effects that would make treatment intolerable. Patient enrollment will continue at the current dose as trial protocols are amended to allow higher dosing. We believe this could indicate that rigosertib can improve response rates for checkpoint inhibitor therapies ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.